Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors.

McKean, M; Tolcher, AW; Reeves, JA; Chmielowski, B; Shaheen, MF; Beck, JT; Orloff, MM; Somaiah, N; Van Tine, BA; Drabick, JJ; Spira, AI; O'byrne, K; Karapetis, CS; Foresto, SA; Movva, S; Martinez, J; Li, MY; Winkler, R; Yang, DJ; Zhai, YF

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索